Eradivir

Eradivir is a small biotechnology company based in the United States, with a team of five dedicated employees. Their core mission revolves around developing innovative immunotherapies to combat viral infections and cancers. Eradivir specializes in creating bispecific molecules that act as bridges, connecting a patient’s own immune cells to targeted viral or cancerous cells. This targeted approach enables a rapid and precise immune response, effectively eliminating the threat while leaving healthy cells unharmed. Eradivir's bispecific immunotherapy platform holds the potential to revolutionize the treatment of numerous diseases, including influenza, various coronaviruses, hepatitis B, HIV, and even certain types of cancer. The company's research focuses on developing a diverse toolkit of these small molecules, each tailored to target specific pathogens or cancer cells. For more information about Eradivir and its groundbreaking research, please visit their website at eradivir.com.